The Cunningham Panel™ helps identify an infection-triggered autoimmune encephalopathy in a child initially diagnosed with schizophrenia.
There was a case of a patient diagnosed with schizophrenia. A 15-year-old girl who was treated and in and out of treatment facilities.
She was originally diagnosed and treated unsuccessfully for schizophrenia, psychosis, severe anxiety and depression. A more in-depth history revealed that she had an abrupt onset of symptoms with remote acute infections exhibited many characteristics of obsessive compulsive disorder (OCD) with rituals.
But her symptoms were uncontrollable. The physician referred her to an immunologist. And the immunologist knew about our testing and submitted a blood sample for us to test.
She had acute onset of “seizure-like spells,” psychotic thinking, and seemingly schizophrenia symptoms, manifesting as auditory hallucinations and catatonic movements.
The patient was positive and began using immunomodulatory therapy.
She was able to be weaned off of olanzapine and resume many of her normal activities, including tennis within 2 weeks after plasmapheresis.
And within a few weeks, this patient, a 15-year-old girl who was diagnosed with schizophrenia, in and out of treatment facilities was back home normal and playing tennis and off of all psychiatric medications.
After 1 course of plasmapheresis was administered (7 treatments every other day), the patient had complete resolution of her psychotic, OCD and anxiety symptoms.
This is dramatic. All these cases may not be so dramatic but the take home message is that once the underlying root cause can be identified, then clinicians can treat the underlying root with the proper medications.
This study was published in a peer-reviewed journal and there are many more [cases] like this.
The authors describe the case of a 15-year-old female who was initially diagnosed and treated unsuccessfully for schizophrenia, psychosis, severe anxiety, and depression.
At age 15, the patient required 4 inpatient psychiatric hospitalizations due to “an acute onset of “seizure-like” spells, psychotic thinking, and seemingly schizophrenic symptoms, manifesting as auditory hallucinations and catatonic movements.”
Her physical symptoms included dysphonia, mouth twitches, echolalia, frequent pacing, frequent cussing, holding her breath, repeatedly asking the same questions, crying and laughing for no reason, staring, outstretching of her arms for 30 minutes, stumbling, worsening dysgraphia, unable to solve math problem, and worsening reading skills.
The patient was treated unsuccessfully with several antipsychotic medications, including one for severe treatment-resistant schizophrenia.
The patient was referred to an immunologist who ordered the Cunningham Panel™. The results indicated a significant elevation of the four autoantibodies and a borderline increase for CaM KII.
“A work-up for underlying infectious, immunodeficiency, and autoimmune causes was unrevealing,” the authors state, “except for very high levels of anti-neuronal antibodies [as measured with the Cunningham Panel] which have been linked to Pediatric Acute-onset Neuropsychiatric Syndrome (PANS).”
“It was decided that plasmapheresis to remove the anti-neuronal antibodies would be most appropriate treatment,” the authors stated.
The patient was treated with one course of plasmapheresis, which led to a complete resolution of her psychotic, OCD, and anxiety symptoms.
She was able to stop the antipsychotic medication and within 2 weeks after stopping plasmapheresis, the patient was able to resume many of her normal activities including tennis.
“This case illustrates the importance of establishing a broad differential diagnosis
including underlying autoimmune encephalopathy, PANDAS/PANS, infection, and other immunologic disorders when evaluating patients presenting with OCD with rituals, severe anxiety, and psychotic symptoms.”
Furthermore, it demonstrates “the importance of exploring nontraditional treatments for severe, treatment-resistant mental illness which requires a multidisciplinary approach.”
Dr. B. Robert Mozayeni was trained in Internal Medicine and Rheumatology at Yale and at NIH. He has had pre- and post-doctoral Fellowships in Molecular Biophysics and Biochemistry at Yale, and also at NIH where he was a Howard Hughes Research Scholar at LMB/DCBD/NCI and later, Senior Staff Fellow at LMMB/NHLBI/NIH. Editorial board of Infectious Diseases – Surveillance, Prevention and Treatment. Past President of the International Lyme and Associated Diseases Society (ILADS).
He is an expert in Translational Medicine, the science and art of advancing medical science safely and efficiently. He is a Fellow of the non-profit Think Lead Innovate Foundation and is a co-founder of the Foundation for the Study of Inflammatory Diseases. He is a Founder of the Foundation for the Study of Inflammatory Diseases to crowd-source medical solutions for complex conditions using existing knowledge, diagnostic methods, and therapies to meet patient needs immediately. He is the Chief Medical Officer of Galaxy Diagnostics, LLC. He is a Board member of the Human-Kind Alliance. Dr. Mozayeni has held admitting privileges (since 1994) on the clinical staff of Suburban Hospital, a member of Johns Hopkins Medicine and an affiliate of the National Institutes of Health Clinical Center.
Dr. Sajo Beqaj is board certified in molecular pathology and genetics and licensed as a Bioanalyst and High Complexity Laboratory Director. He has been practicing as a laboratory director since 2005.
Dr. Beqaj served as a technical director and was part of the initial management team for several well-known laboratories in the clinical lab industry including PathGroup, Nashville, TN; DCL Medical Laboratories, Indianapolis, IN, and Pathology, Inc, Torrance, CA. He is currently serving as off-side CLIA laboratory director for BioCorp Clinical Laboratory, Whittier, CA and Health360 Labs, Garden Grove, CA.
Dr. Beqaj received his Ph.D. in Pathology from Wayne State University Medical School, Detroit, Michigan. He performed his post-doctoral fellowship at Abbott Laboratories from 2001-2003 and with Children’s Hospital and Northwestern University from 2003-2005.
Dr. Beqaj has taught in several academic institutions and has published numerous medical textbook chapters and journal articles. He has served as a principal investigator in clinical trials for several well-known pharmaceutical and diagnostic companies such as Roche HPV Athena, Merck HPV vaccine, BD vaginitis panel, Roche (Vantana) CINtec® Histology clinical trials, and has presented various scientific clinical abstracts and presentations.
He is a member of several medical and scientific associations including the Association of Molecular Pathology, American Association of Clinical Chemistry and the Pan Am Society for Clinical Virology. He has served on a number of clinical laboratory regulatory and scientific committees, and has assisted several laboratories and physicians as a Clinical Laboratory Consultant.